S2 Fig -

<p>Prescribed doses of antiparkinsonian drugs during the observation period for the improved, unchanged, and deteriorated groups of patients: (A) pergolide, (B) cabergoline, (C) pramipexole, (D) ropinirole, (E) apomorphine, (F) rotigotine, (G) entacapone, (H) selegiline, (I) zonisamide, (J) amantadine, (K) istradefylline, and (L) droxidopa. Values are estimates ± standard error. The number of patients (%) prescribed each drug at baseline is indicated. *P < 0.05 for the improved group vs. the unchanged and deteriorated groups at Week 52 (generalized linear model).</p> <p>(PDF)</p>